Season 3 - Ep.11: AI and the future of the electrocardiogram - The heart in rheumatic disorders and autoimmune diseases

6 snips

Mar 13, 2025

Carlos Aguiar, a contributor to Cardiology This Week, joins Paul Friedman, a leading expert on AI-based ECG interpretation at the Mayo Clinic. They delve into the transformative potential of artificial intelligence in ECG analysis, showcasing a neural network that enhances heart function assessment. The discussion links cardiovascular health with autoimmune disorders, unpacking the increased risks these patients face. Additionally, they explore the essentials of Bayesian analysis in medicine, highlighting its role in improving diagnostic accuracy and patient care.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

AI-ECG Capabilities

AI-powered ECGs can identify left ventricular dysfunction with high accuracy (AUC of 0.92).
AI can also deduce patient age and sex from ECGs, creating an "age gap" biomarker.

INSIGHT

Predictive Power of AI-ECGs

AI can predict future heart conditions by recognizing subtle ECG changes often missed by humans.
This "predictive" ability stems from AI's capacity to detect hidden patterns indicating early disease.

ADVICE

ECG Recording Method

Use digital ECGs for AI analysis, as other formats reduce accuracy.
Digital ECGs allow for better processing and maintain data quality.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

This episode covers:

Cardiology This Week: A concise summary of recent studies
AI and the future of the Electrocardiogram
The heart in rheumatic disorders and autoimmune diseases
Statistics Made Easy: Bayesian analysis

Host: Susanna Price

Guests: Carlos Aguiar, Paul Friedman, Maya Buch

Want to watch that episode? Go to: https://esc365.escardio.org/event/1801

Disclaimer:

ESC TV Today is supported by Bristol Myers Squibb.

This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor.

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

Declarations of interests:

Stephan Achenbach, Antonio Greco, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

Maya Buch has declared to have potential conflicts of interest to report: grant/research support paid to University of Manchester from Gilead and Galapagos; consultant and/or speaker with funds paid to University of Manchester for AbbVie, Boehringer Ingelheim, CESAS Medical, Eli Lilly, Galapagos, Gilead Sciences, Medistream and Pfizer Inc; member of the Speakers’ Bureau for AbbVie with funds paid to University of Manchester.

Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo.

Paul Friedman has declared to have potential conflicts of interest to report: co-inventor of AI ECG algorithms.

Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.